BTIG Research Initiates Coverage on Arcturus Therapeutics (NASDAQ:ARCT)

BTIG Research initiated coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a research report released on Tuesday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $41.00 target price on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the company. HC Wainwright reiterated a “buy” rating and set a $63.00 price target on shares of Arcturus Therapeutics in a research report on Monday, January 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, December 16th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $61.60.

Arcturus Therapeutics Trading Up 3.4 %

Shares of ARCT opened at $17.42 on Tuesday. Arcturus Therapeutics has a 12 month low of $14.30 and a 12 month high of $45.00. The company has a market capitalization of $471.91 million, a price-to-earnings ratio of -7.85 and a beta of 2.63. The stock has a 50 day moving average of $17.26 and a 200 day moving average of $19.54.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.44. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The company had revenue of $41.67 million for the quarter, compared to analysts’ expectations of $49.16 million. During the same quarter in the previous year, the firm posted ($0.61) EPS. As a group, equities research analysts predict that Arcturus Therapeutics will post -2.31 earnings per share for the current year.

Institutional Trading of Arcturus Therapeutics

Large investors have recently modified their holdings of the business. nVerses Capital LLC purchased a new stake in shares of Arcturus Therapeutics in the 3rd quarter worth about $42,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Arcturus Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock valued at $121,000 after acquiring an additional 2,038 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Arcturus Therapeutics in the second quarter worth about $142,000. SG Americas Securities LLC purchased a new stake in Arcturus Therapeutics during the 3rd quarter valued at $191,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Arcturus Therapeutics by 10.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company’s stock worth $202,000 after buying an additional 846 shares in the last quarter. 94.54% of the stock is owned by institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.